Background. Tumor recurrence represents the main limitation of liver transplantation in patients with hepatocellular carcinoma (HCC) and can be favored by exposure to calcineurin inhibitors. Methods. We investigated the effect of an immunosuppressant schedule that minimizes the exposure to calcineurin inhibitors on patients transplanted for HCC to ascertain whether this can reduce the tumor recurrence rate. For this purpose, we conducted a matched-cohort study: 31 patients with HCC transplanted between 2004 and 2007 who received sirolimus as part of their immunosuppression (group A) were compared with a control group of 31 patients (group B) transplanted in the same period who had the same prognostic factors but were given standard immunosuppression based on tacrolimus. RESULTS.: Three-year recurrence-free survival was 86% in group A and 56% in group B (P=0.04). Although the prevalence of microvascular invasion G3-G4 grading and alpha-fetoprotein more than 200 ng/mL was identical in the two groups, exposure to tacrolimus was significantly higher in patients of group B (median, 8.54; range, 5.5-13.5) in comparison with those of group A (median, 4.6; range, 1.8-9.1) (P=0.0001). Conclusions. By using sirolimus, exposure to calcineurin inhibitors can be minimized, reducing the risk of HCC recurrence. Copyright © 2010 by Lippincott Williams & Wilkins.

Effect of different immunosuppressive schedules on recurrence-free survival after liver transplantation for hepatocellular carcinoma / VIVARELLI, MARCO; DAZZI, ALESSANDRO; ZANELLO, MATTEO; CUCCHETTI, ALESSANDRO; CESCON, MATTEO; RAVAIOLI, MATTEO; DEL GAUDIO, MASSIMO; Lauro A; GRAZI, GIAN LUCA; PINNA, ANTONIO DANIELE. - In: TRANSPLANTATION. - ISSN 0041-1337. - STAMPA. - 89:(2010), pp. 227-231. [10.1097/TP.0b013e3181c3c540]

Effect of different immunosuppressive schedules on recurrence-free survival after liver transplantation for hepatocellular carcinoma

GRAZI, GIAN LUCA;
2010

Abstract

Background. Tumor recurrence represents the main limitation of liver transplantation in patients with hepatocellular carcinoma (HCC) and can be favored by exposure to calcineurin inhibitors. Methods. We investigated the effect of an immunosuppressant schedule that minimizes the exposure to calcineurin inhibitors on patients transplanted for HCC to ascertain whether this can reduce the tumor recurrence rate. For this purpose, we conducted a matched-cohort study: 31 patients with HCC transplanted between 2004 and 2007 who received sirolimus as part of their immunosuppression (group A) were compared with a control group of 31 patients (group B) transplanted in the same period who had the same prognostic factors but were given standard immunosuppression based on tacrolimus. RESULTS.: Three-year recurrence-free survival was 86% in group A and 56% in group B (P=0.04). Although the prevalence of microvascular invasion G3-G4 grading and alpha-fetoprotein more than 200 ng/mL was identical in the two groups, exposure to tacrolimus was significantly higher in patients of group B (median, 8.54; range, 5.5-13.5) in comparison with those of group A (median, 4.6; range, 1.8-9.1) (P=0.0001). Conclusions. By using sirolimus, exposure to calcineurin inhibitors can be minimized, reducing the risk of HCC recurrence. Copyright © 2010 by Lippincott Williams & Wilkins.
2010
89
227
231
VIVARELLI, MARCO; DAZZI, ALESSANDRO; ZANELLO, MATTEO; CUCCHETTI, ALESSANDRO; CESCON, MATTEO; RAVAIOLI, MATTEO; DEL GAUDIO, MASSIMO; Lauro A; GRAZI, GIAN LUCA; PINNA, ANTONIO DANIELE
File in questo prodotto:
File Dimensione Formato  
2010 (Transplantation) Vivarelli - Immunosuppression.pdf

Accesso chiuso

Dimensione 302.65 kB
Formato Adobe PDF
302.65 kB Adobe PDF   Richiedi una copia

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/1301244
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 102
  • ???jsp.display-item.citation.isi??? 97
social impact